Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Current Assets (2016 - 2025)

Historic Current Assets for Abvc Biopharma (ABVC) over the last 14 years, with Q3 2025 value amounting to $4.1 million.

  • Abvc Biopharma's Current Assets rose 8756.47% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year increase of 8756.47%. This contributed to the annual value of $2.2 million for FY2024, which is 3157.5% up from last year.
  • As of Q3 2025, Abvc Biopharma's Current Assets stood at $4.1 million, which was up 8756.47% from $2.8 million recorded in Q2 2025.
  • Abvc Biopharma's 5-year Current Assets high stood at $9.8 million for Q2 2022, and its period low was $1.5 million during Q1 2025.
  • Moreover, its 5-year median value for Current Assets was $2.9 million (2022), whereas its average is $3.9 million.
  • Its Current Assets has fluctuated over the past 5 years, first skyrocketed by 50376.1% in 2021, then tumbled by 7825.38% in 2023.
  • Abvc Biopharma's Current Assets (Quarter) stood at $7.7 million in 2021, then crashed by 60.97% to $3.0 million in 2022, then plummeted by 44.54% to $1.7 million in 2023, then skyrocketed by 31.58% to $2.2 million in 2024, then skyrocketed by 86.83% to $4.1 million in 2025.
  • Its Current Assets stands at $4.1 million for Q3 2025, versus $2.8 million for Q2 2025 and $1.5 million for Q1 2025.